Sonnet BioTherapeutics Holdings, Inc. Overview
Pro stress-test →Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company that developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. However, Hyperliquid Strategies (NASDAQ:PURR) completed a business combination with Sonnet BioTherapeutics (NASDAQ:SONN) and Rorschach I LLC, effective Dec 2, 2025.
Strategic Profile
Pro stress-test →Pre-merger, Sonnet leveraged a fully human single-chain antibody fragment designed to bind human serum albumin and transport large-molecule therapies toward tumor and lymphatic tissue, supporting constructs that include cytokines, peptides, antibodies and vaccines. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others. As of the merger, the company is now focused on cryptocurrency holdings rather than drug development.
Competitive Landscape
Pro stress-test →In its original biotechnology form, Sonnet competed in clinical-stage oncology immunotherapeutics, a crowded space including companies like Jounce Therapeutics, Tmunity Therapeutics, and other IL-12/IL-15-focused immunotherapy developers. Post-merger transformation eliminates direct biotech competition but positions company within crypto-treasury holding sector.
Industry Context
Sonnet BioTherapeutics Holdings, Inc. operates in Clinical-stage oncology immunotherapeutics (pre-merger).
Key facts
Founded: 2009 · Headquarters: Princeton, US · Employees: Unknown · Revenue: N/A (pre-commercial biotech) · Market cap: $8.6M (as of June 1, 2026)